Tracking Triple-negative Breast Cancer Evolution Through Therapy
Tracking Triple-negative Breast Cancer Evolution Through Therapy
A prospective multicentre study which aims to examine the relationship between intratumour
 heterogeneity (ITH) and pathological response to neoadjuvant chemotherapy in patients with
 histological confirmation of triple-negative breast cancer (TNBC) who are eligible for
 neoadjuvant chemotherapy.
Inclusion Criteria:

 1. Age 18-years or older

 2. Patients with histological confirmation of invasive breast cancer with known receptor
 status suitable for neoadjuvant chemotherapy as assessed by the local investigator

 3. Estrogen receptor (ER)- and progesterone receptor (PR)-negative as defined by ≤1% of
 positive staining on immunohistochemistry

 4. Human epidermal growth factor receptor 2 (HER2)-negative as defined by American
 Society of Clinical Oncology / College of American Pathologists guidelines

 5. T1c-4 tumours (including inflammatory cancers), with any nodal status non candidate
 for conservative surgery upfront. Bilateral or multifocal cancer is permitted provided
 that all sites are HER2-negative and at least one site is ER- and PR-negative.

 6. Provision of signed and dated, written informed consent prior to any study specific
 procedures, sampling and analyses

 7. Patient with social insurance coverage

 Exclusion Criteria:

 1. Confirmed metastatic disease at initial presentation

 2. Any contraindication to the biopsy procedure

 3. Previous or current malignancies of other origin within the last 5 years, with the
 exception of in situ carcinoma of the cervix, and adequately treated basal cell or
 squamous cell carcinoma of the skin

 4. Any condition which in the Investigator's opinion makes it undesirable for the subject
 to participate in the trial or which would jeopardize compliance with the protocol

 5. Individuals deprived of liberty or placed under the authority of a tutor